Journal of Digestive Cancer Research

  • 제12권2호
  • /
  • Pages.72-81
  • /
  • 2024
  • /
  • 2950-9394(pISSN)
  • /
  • 2950-9505(eISSN)
대한소화기암연구학회 (Korean Society of Gastrointestinal Cancer Research)
권호 표지
DOI QR코드

DOI QR Code

진행성/전이성 식도 편평상피세포암의 면역치료

Immunotherapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma

  • 김성은 (고신대학교 의과대학 내과학교실) ;
  • 정경원 (고신대학교 의과대학 내과학교실) ;
  • 박무인 (고신대학교 의과대학 내과학교실)
  • Sung Eun Kim (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Kyoungwon Jung (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Moo In Park (Department of Internal Medicine, Kosin University College of Medicine)
  • 투고 : 2024.07.08
  • 심사 : 2024.07.25
  • 발행 : 2024.08.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Esophageal squamous cell carcinomas constitute a major proportion of esophageal cancers in Korea. Conventional chemotherapy and radiation therapy are the options for treating advanced/metastatic esophageal cancer, but the prognosis remains poor. Immunotherapy has significantly improved the prognosis of several advanced/metastatic cancers including esophageal squamous cell carcinoma. In Korea, immunotherapy is used to treat advanced/metastatic esophageal squamous cell carcinoma, and treatment results are expected to further improve. Immunotherapy is a term used to describe a treatment modality involving a biological/targeted agent that aims to enhance and restore the ability of the immune system to detect and destroy cancer cells by modifying or blocking co-stimulating signals. Immune checkpoint inhibitors have revolutionized cancer treatment with the administration of a single agent (monotherapy) or combinations of multiple agents, with the three approved agents being anti-PD-1 (programmed death 1), anti-PD-L1 (programmed cell death ligand 1), and anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) monoclonal antibodies. Anti-PD-1 drugs including nivolumab and pembrolizumab have been mainly investigated for treating advanced/metastatic esophageal squamous cell cancer. Studies on their effectiveness in a neoadjuvant setting, a curative adjuvant setting, or as the first-line treatment for advanced or metastatic setting are ongoing. This review describes the principle of action, summary of existing clinical studies, and prospects for immune checkpoint inhibitors used in the treatment of advanced/metastatic esophageal squamous cell cancer.

키워드

참고문헌

  1. World Health Organization. Global Cancer Observatory. International agency for research on cancer. https://gco.iarc.who.int/media/globocan/factsheets/cancers/6-oesophagus-fact-sheet.pdf (accessed July 1, 2024) 
  2. Park SY, Kim DJ. Esophageal cancer in Korea: epidemiology and treatment patterns. J Chest Surg 2021;54:454-459. https://doi.org/10.5090/jcs.21.039 
  3. Cho JH. A new chemotherapy paradigm in advanced esophageal cancer. J Dig Cancer Res 2022;10:43-45. https://doi.org/10.52927/jdcr.2022.10.1.43 
  4. National Cancer Infomation Center. Esophageal cancer. 2013. https://www.cancer.go.kr/lay1/program/S1T211C223/cancer/view.do?cancer_seq=4277 (accessed July 1, 2024) 
  5. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-387. https://doi.org/10.1016/j.ejca.2018.07.005 
  6. Park MI. Chemoradiotherapy for esophageal cancer. Korean J Helicobacter Up Gastrointest Res 2019;19:161-168. https://doi.org/10.7704/kjhugr.2019.19.3.161 
  7. Shoji Y, Koyanagi K, Kanamori K, et al. Immunotherapy for esophageal cancer: where are we now and where can we go. World J Gastroenterol 2024;30:2496-2501. https://doi.org/10.3748/wjg.v30.i19.2496 
  8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. https://doi.org/10.1056/NEJMoa1003466 
  9. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-218. https://doi.org/10.1038/nature12213 
  10. Shi T, Ma Y, Yu L, et al. Cancer immunotherapy: a focus on the regulation of immune checkpoints. Int J Mol Sci 2018;19:1389. https://doi.org/10.3390/ijms19051389 
  11. Elpek KG, Cremasco V, Shen H, et al. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunol Res 2014;2:655-667. https://doi.org/10.1158/2326-6066.CIR-13-0209 
  12. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-5912. https://doi.org/10.1038/onc.2008.271 
  13. Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy 2020;12:203-218. https://doi.org/10.2217/imt2019-0153 
  14. Digklia A, Duran R, Homicsko K, et al. Cancer immunotherapy: a simple guide for interventional radiologists of new therapeutic approaches. Cardiovasc Intervent Radiol 2019;42:1221-1229. https://doi.org/10.1007/s00270-018-2074-1 
  15. de Mello RA, Veloso AF, Esrom Catarina P, Nadine S, Antoniou G. Potential role of immunotherapy in advanced non-small-cell lung cancer. Onco Targets Ther 2016;10:21-30. https://doi.org/10.2147/OTT.S90459 
  16. Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond) 2019;39:79. https://doi.org/10.1186/s40880-019-0427-z 
  17. Hogner A, Thuss-Patience P. Immune checkpoint inhibition in oesophago-gastric carcinoma. Pharmaceuticals (Basel) 2021;14:151. https://doi.org/10.3390/ph14020151 
  18. Sudo T, Nishida R, Kawahara A, et al. Clinical impact of tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Ann Surg Oncol 2017;24:3763-3770. https://doi.org/10.1245/s10434-017-5796-4 
  19. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an openlabel, multicentre, phase 2 trial. Lancet Oncol 2017;18:631-639. https://doi.org/10.1016/S1470-2045(17)30181-X 
  20. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506-1517. https://doi.org/10.1016/S1470-2045(19)30626-6 
  21. Okada M, Kato K, Cho BC, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res 2022;28:3277-3286. https://doi.org/10.1158/1078-0432.CCR-21-0985 
  22. Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386:449-462. https://doi.org/10.1056/NEJMoa2111380 
  23. Kato K, Doki Y, Chau I, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med 2024;13:e7235. https://doi.org/10.1002/cam4.7235 
  24. Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol 2018;36:61-67. https://doi.org/10.1200/JCO.2017.74.9846 
  25. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 Study. JAMA Oncol 2019;5:546-550. https://doi.org/10.1001/jamaoncol.2018.5441 
  26. Kojima T, Shah MA, Muro K, et al.; KEYNOTE-181 Investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 2020;38:4138-4148. https://doi.org/10.1200/JCO.20.01888 
  27. Sun JM, Shen L, Shah MA, et al.; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759-771. https://doi.org/10.1016/S0140-6736(21)01234-4 
  28. Lee MA. Understanding immunochemotherapy. J Kor Soc Health-syst Pharm 2020;37:255-264. 
  29. Shen L, Kato K, Kim SB, et al.; RATIONALE-302 Investigators. Tislelizumab versus chemotherapy as secondline treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol 2022;40:3065-3076. https://doi.org/10.1200/JCO.21.01926 
  30. Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 2022;40:277-288.e3. https://doi.org/10.1016/j.ccell.2022.02.007 
  31. Luo H, Lu J, Bai Y, et al.; ESCORT-1st Investigators. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 2021;326:916-925. https://doi.org/10.1001/jama.2021.12836 
  32. Shen L, Lu ZH, Wang JY, et al. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study. Ann Oncol 2021;32:S1330. https://doi.org/10.1016/j.annonc.2021.08.2132 
  33. Lu Z, Wang J, Shu Y, et al.; ORIENT-15 study group. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 2022;377:e068714. https://doi.org/10.1136/bmj-2021-068714 
  34. Park S, Oh D, Choi YL, et al. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancer 2022;128:2148-2158. https://doi.org/10.1002/cncr.34176 
  35. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 2018; 29:2052-2060. https://doi.org/10.1093/annonc/mdy264 
  36. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5 
  37. Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol 2020;21:e419-e430. https://doi.org/10.1016/S1470-2045(20)30234-5 
  38. Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 2020;38:2053-2061. https://doi.org/10.1200/JCO.19.03296 
  39. Hironaka S, Kadowaki S, Izawa N, et al. A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. J Clin Oncol 2020;38(4 Suppl):352. https://doi.org/10.1200/JCO.2020.38.4_suppl.352